6 Results for "

B16-BL6

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "B16-BL6" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-125864
CAS No.: 9001-32-5
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
loading...
    loading...
Cat. No.: HY-W011963
CAS No.: 1421-65-4
Synonyms: Levodopa methylester hydrochloride
Melevodopa (Levodopa methylester) hydrochloride is an orally active methylated prodrug of Levodopa (HY-N0304), a dopamine precursor. When used in combination with Carbidopa (HY-B0311) in an effervescent tablet formulation, Melevodopa hydrochloride inhibits motor fluctuations in Parkinson's disease. Melevodopa hydrochloride suppresses subcutaneous tumor growth, pulmonary metastasis proliferation, and primary mass invasiveness of melanoma. Melevodopa hydrochloride induces lipid peroxidation by increasing malondialdehyde levels in melanoma and improves the survival rate of melanoma-bearing mice. Melevodopa hydrochloride can be used in research related to Parkinson's disease (with motor fluctuations) and melanoma .
loading...
    loading...
Cat. No.: HY-P1189
CAS No.: 154303-05-6
Echistatin is a naturally derived RGD-containing snake venom peptide. Echistatin exhibits an IC50 of 0.6 nM against mouse αvβ3 integrin, and acts as an antagonist against αvβ3, αII3, α5β1 integrins, pp125 FAK and paxillin. Echistatin reduces the phosphorylation of pp125 FAK and paxillin, inhibits the autophosphorylation and kinase activity of pp125 FAK, and weakens its binding to pp60src and paxillin. Echistatin disrupts the actin cytoskeleton and focal adhesions, induces melanoma cell detachment from fibronectin, and regulates cell adhesion and motility. Echistatin inhibits osteoclast maturation and migration, bone resorption, platelet aggregation, bone loss, as well as adhesion and metastasis of Lewis lung cancer cells; it also increases the number of osteoclasts and bone coverage area in mice with secondary hyperparathyroidism. Echistatin can be used in research related to melanoma, lung cancer and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-P1189A
Echistatin TFA is a naturally derived RGD-containing snake venom peptide. Echistatin TFA exhibits an IC50 of 0.6 nM against mouse αvβ3 integrin, and acts as an antagonist against αvβ3, αII3, α5β1 integrins, pp125 FAK and paxillin. Echistatin TFA reduces the phosphorylation of pp125 FAK and paxillin, inhibits the autophosphorylation and kinase activity of pp125 FAK, and weakens its binding to pp60src and paxillin. Echistatin TFA disrupts the actin cytoskeleton and focal adhesions, induces melanoma cell detachment from fibronectin, and regulates cell adhesion and motility. Echistatin TFA inhibits osteoclast maturation and migration, bone resorption, platelet aggregation, bone loss, as well as adhesion and metastasis of Lewis lung cancer cells; it also increases the number of osteoclasts and bone coverage area in mice with secondary hyperparathyroidism. Echistatin TFA can be used in research related to melanoma, lung cancer and secondary hyperparathyroidism .
loading...
    loading...
Cat. No.: HY-N14163
CAS No.: 220766-06-3
Diperamycin has activity against Gram-positive bacteria, including Enterococcus seriolicida and MRSA (MICs of 0.10-0.20 μg/mL). Diperamycin also strongly inhibits the activity of L1210, P388, LS-180, KB, HeLaS3, Meth A and B16-BL6 (IC50s of 0.009-0.098 μg/mL) .
loading...
    loading...
Cat. No.: HY-122278
CAS No.: 7101-51-1
Synonyms: Levodopa methylester
Melevodopa (Levodopa methylester) is an orally active methylated prodrug of Levodopa (HY-N0304), a dopamine precursor. When used in combination with Carbidopa (HY-B0311) in an effervescent tablet formulation, Melevodopa inhibits motor fluctuations in Parkinson's disease. Melevodopa suppresses subcutaneous tumor growth, pulmonary metastasis proliferation, and primary mass invasiveness of melanoma. Melevodopa induces lipid peroxidation by increasing malondialdehyde levels in melanoma and improves the survival rate of melanoma-bearing mice. Melevodopa can be used in research related to Parkinson's disease (with motor fluctuations) and melanoma .
loading...
    loading...